What compounds target PRKD2?

BiohacksAI has identified 44 compounds that interact with PRKD2 (protein kinase D2). Top compounds include: alvocidib, palbociclib, bi 2536, midostaurin, brigatinib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is PRKD2 (protein kinase D2)?

PRKD2 is protein kinase D2. It is a molecular target for 44 compounds documented in PubMed bioassay data. UniProt ID: Q9BZL6. NCBI Gene ID: 25865.

PRKD2

MOLECULAR TARGET

protein kinase D2

UniProt: Q9BZL6 NCBI Gene: 2586544 compounds

PRKD2 (protein kinase D2) is targeted by 44 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PRKD2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	alvocidib	4.52	91
2	palbociclib	4.22	67
3	bi 2536	4.01	54
4	midostaurin	3.85	46
5	brigatinib	3.81	44
6	neratinib	3.66	38
7	abemaciclib	3.66	38
8	fasudil	3.66	38
9	nintedanib	3.61	36
10	bms 387032	3.47	31
11	tae 684	3.43	30
12	dabrafenib	3.30	26
13	ribociclib	3.26	25
14	at 9283	3.09	21
15	lestaurtinib	3.04	20
16	pf 03758309	3.00	19
17	ruboxistaurin	2.94	18
18	danusertib	2.94	18
19	momelotinib	2.89	17
20	k 252a	2.83	16
21	milciclib	2.77	15
22	pf 00562271	2.77	15
23	capivasertib	2.77	15
24	azd 5438	2.71	14
25	kw 2449	2.64	13
26	ast 487	2.56	12
27	zotiraciclib	2.56	12
28	ulixertinib	2.56	12
29	ripasudil	2.40	10
30	hydroxyfasudil	2.40	10
31	azd 7762	2.30	9
32	su 014813	2.20	8
33	gsk 1070916	2.20	8
34	y 39983	2.20	8
35	cyc 116	2.08	7
36	asp 3026	2.08	7
37	amg 900	2.08	7
38	uprosertib	1.95	6
39	pf 03814735	1.79	5
40	ucn 01	1.79	5
41	afuresertib	1.79	5
42	hydroxyfasudil [Supplementary Concept]	1.39	3
43	Crizotinib	0.69	1
44	sp600125	0.69	1

About PRKD2 as a Drug Target

PRKD2 (protein kinase D2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 44 compounds with documented PRKD2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PRKD2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.